AbbVie and Genmab's blood-cancer drug Epkinly showed a competitive profile in a late-stage lymphoma trial that boosts confidence in its potential, Bank of America analysts say in a research note. Strong results for a drug combination including Epkinly as a second-line treatment for diffuse large B-cell lymphoma support confidence in its potential to move to the first line of therapy, the analysts say. The study results can drive investor sentiment on Danish biotech company Genmab ahead of a busy second half, they add. Genmab is due to release data on two wholly-owned drugs--Rina-S in ovarian cancer and petosemtamab in head and neck cancer--that are expected to become core assets for the company, the analysts say. Each represents a $2 billion sales opportunity, according to Bank of America. Genmab shares rise 5.3%. (adria.calatayud@wsj.com)